Opinion|Videos|July 12, 2024
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
2
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
3
United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF
4
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
5